Mariano Musacchio 1 François Sellal 2 Frédéric Blanc 2 Jean-Marc Michel 2 Stephan Kremer 3 Jean-Louis Dietemann 3 1 Department of Neuroradiology - CHG.

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Department of Neurology, Mayo Clinic Arizona
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Frontotemporal Dementia
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
Dementia & Delirium in Surgical Patients Damian Harding Department of Geriatric Medicine February 2008.
Dementia Patients Caregivers Quality of Life International Journal of Geriatric Psychiatry Karine Demeule.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Dementia with Lewy Bodies
Mild Cognitive Impairment
MILD COGNITIVE IMPAIRMENT IN PATIENTS WITH CAROTID DISEASE Irena Martinic Popovic 1, M.D, Arijana Lovrencic-Huzjan 1, M.D, Ph. D, Ana-Maria Simundic 2,
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Alzheimer's Disease – Current Status; Future Perspectives
Dementia. Definition Loss of function in multiple cognitive abilities Assuming the individual had normal abilities before the onset Many of the 70 recognized.
How Alzheimer’s Disease Differs from Frontal Temporal Lobe Dementia (Pick’s Disease) Josepha A. Cheong, MD University of Florida Departments of Psychiatry.
A 67-year-old male with behavioral and language problems
Nice guidelines Definition  Widespread deterioration in cerebral function without impairment of consciousness.  Occurs across a widespread of.
Diagnostic Memory Clinic & Dementia Services
Recognition of Dementia Syed Zaman Consultant Physician Geriatric Medicine Palmerston North Hospital.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
M. Alzheimer. Etiopatogenesis patological proteins u neuritic plaques u  amyloid u amyloid precursor protein (APP)  sekretase  sekretase  amyloid.
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada.
بسم الله الرحمن الرحیم. Dementia Dementia is a condition characterised by a progressive decline of mental abilities accompanied by changes in personality.
Dementia Reed Radford. What is dementia?  Dementia is a serious loss of global cognitive ability, beyond what might be expected from normal aging. 
Alzheimer’s Disease Landscape
Mild Cognitive Impairment
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
Advancing research diagnostic criteria for Alzheimer's disease: implications for drug development and public health management Jean François Dartigues.
Parkinson’s Plus By: Glen Estrosos.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
Laurence Lacoste Ph. D, Paris, France 1*. Introduction : Why ?  Population’s Ageing is a Public Health issue and dementia for the Elderly a reality 
Dr Hussein Farghaly PSMMC
Dementia 痴呆 Jie Ming Shen, M.D., Ph.D. Department of Neurology Ruijin Hospital, SSMU.
How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.
Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.
HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.
MCI Conversion to Dementia: Clinic and Community-Based Studies
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
Jalal Jalal Shokouhi – MD
Assessment and Diagnosis of Dementia Dr Alison Haddow.
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
Alabama Brief Cognitive Screener (ABCs)
Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.
NON PHARMACOLOGICAL THERAPY OF MENTAL IMAGERY AND RELAXATION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT Poptsi Ε.,1,3, Κounti F.,1,3,Τsolaki, Μ. 1,2 1.
BY: GRACE STOUT. What is Alzheimer’s and what does it do to the human body?  Alzheimer’s Disease is a progressive, neurodegenerative disorder that is.
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
Seniors with Memory Loss: A Primer Praveen Dayalu, MD Clinical Associate Professor Department of Neurology University of Michigan.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Frontotemporal Lobar Degeneration:
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Alzheimer Disease: An Overview. What is Dementia? Dementia is a set of symptoms, which includes loss of memory, understanding, and judgment.
The Malfunctioning Mind: Degenerative Diseases of the Brain
Investigating dementia
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,
Presenter : Dr Aneelraj Co investigators : Dr Srikala Bharath
פסיכוגריאטריה ד''ר שורצמן בי''ח פלימן.
Imaging AD Progression Amyloid Imaging Agents.
Brain Tech TIME Case Study: FDG PET IMAGING IN DEMENTIA (FTD vs AD)
First they said she had schizophrenia and now she cant remember
Nat. Rev. Neurol. doi: /nrneurol
Early Dementia Distinguishing AD From MCI
Nat. Rev. Neurol. doi: /nrneurol
Chapter 30 Delirium and Dementia
Chapter 93 Dementias and Related Disorders
Imaging in dementia / cognitive impairment
Transmissible human proteopathies: an expanding field
Presentation transcript:

Mariano Musacchio 1 François Sellal 2 Frédéric Blanc 2 Jean-Marc Michel 2 Stephan Kremer 3 Jean-Louis Dietemann 3 1 Department of Neuroradiology - CHG Colmar 2 CMRR Strasbourg-Colmar 3 Department of Neuroradiology - CHU Strasbourg Neuroimaging and clinical spectrum of hippocampal sclerosis dementia

Hippocampal sclerosis Definition : Localized hippocampal neuronal loss and astrocytic gliosis, with predilection for CA1 and subiculum. Non epileptic elderly and/or demented patients a,b,c,d : Probst et al, 2007 e,f : Duvernoy e e f

Hippocampal sclerosis dementia Introduction Hippocampal sclerosis dementia FTLD FTD-ALS Alzheimer disease Argyrophilic grain disease Corticobasal degeneration Dementia with Lewy bodies Vascular dementia

Hippocampal sclerosis dementia Introduction The term hippocampal sclerosis dementia designates the presence of both hippocampal sclerotic lesions and a dementia syndrome

Purpose Hippocampal sclerosis dementia To describe neuroradiological findings and analyse clinical presentation of hippocampal sclerosis dementia

9 patients (Colmar + Strasbourg in 4 years) Cognitive troubles or dementia Ecmnesia (anterograde memory) Hippocampal atrophy + sclerosis (T2/FLAIR, or after anatomopathological analysis) Population Hippocampal sclerosis dementia

Hypertension 3/9 Arrhythmia 1/9 Hypercholesterolemia2/9 Diabetes2/9 Smoking1/9 Antecedents Hippocampal sclerosis dementia Cardiovascular risk factors

Score / Mean initial MMSE = 25,2 Initial MMSE Hippocampal sclerosis dementia

MemoryXXXXXXXXX Visuo- constructive Apraxia XX AttentionXX Spatial Disorientation Facial Recognition XX Language Compartmental Troubles Sleep Disorder X Initial symptoms Hippocampal sclerosis dementia

Bilateral9 /9 R = L4 R > L2 R < L3 Hippocampal anomalies Anterior5 /9 Extended4 /9 Hippocampal sclerosis dementia

NAA/CrNAA/Cho+Cr Left hippocampus0,66* 0,35* Left peri-atrial area1,90 1,13 Case 3

Mild Cognitive Impairment 3 patients (n°2, 8, 9) Mild dementia, Alzheimer type 2 patients (n°4, 5) Moderate dementia, Alzheimer type 1 patient (n°1) Focal atrophy1 patient (n°3) Frontotemporal dementia 2 patients (n° 6,7) Initial Diagnosis Hippocampal sclerosis dementia

Final Diagnosis Hippocampal sclerosis dementia Frontotemporal lobar degeneration Alzheimer disease Mild Cognitive Impairment Focal atrophy Frontotemporal lobar degeneration 1 case 7 cases 3 cases 1 case 4 cases

Age at admission: Mean = 71,7 y-o [52-94] Diagnostic delay: Mean = 26 months [6 m - 6 y] Time of evolution: Mean = 63 months [ y] Evolution Hippocampal sclerosis dementia

How? Hippocampal sclerosis dementia SPECT Temporal bilateral5 Temporal unilateral1 Fronto-temporal1 Biparietal1 8/8 non Alzheimer patients

How? Hippocampal sclerosis dementia CSF AD Biomarkers Aβ protNormal ↓ TauNormal P-tauNormal 6/8 non Alzheimer patients

Final Diagnosis Hippocampal sclerosis dementia Frontotemporal lobar degeneration Alzheimer disease Mild Cognitive Impairment Focal atrophy Frontotemporal lobar degeneration 1 case 7 cases 3 cases 1 case 4 cases

Monsieur R.C., 67 years old (2000) Antecedents : Diabetes Depression Complaints (wife) : Anxiety Memory troubles (anterograde) Difficulties in identifying people Independent, but less active

MMS = 29/30 Test de l’horloge = sp Mattis rating scale = 136/144 Attention = normal Judgement and abstraction = normal History recalls = abnormal Monsieur R.C., 67 years old (2000)

RL/RI-16 (Grober & Buschke) immediate recall : 16/16 free recalls : 5*-4*-8* (total : 17*) total recalls : 8*-8*-9* (total : 25*) recognition : 15/16 fausses reconnaissances : 0 deferred free recall : 9*/16 deferred total recall : 10*/16 intrusions : 13* Monsieur R.C., 67 years old (2000)

Isolated memory trouble Independent MCI (Mild Cognitive Impairment) Prodromal Alzheimer disease Monsieur R.C., 67 years old (2000) ?

Monsieur RC, evolution 5-word testTotal scoreIntrusions April 20017/103 August 20039/101 September /100 October /100 May /100

MMSETotal scoreerreurs April memory 2/3 October id October id February memory 2/3 language 7/8 March memory 1/3 language 7/8 May memory 1/3 February memory 0/3 language 7/8 Monsieur RC, evolution

Hippocampal sclerosis dementia Hippocampal sclerosis in dementia Clinical and radiologic follow-up ! Sligthly progressive isolated memory trouble No visuoconstructive apraxia in > 3-y follow-up No topographic memory trouble in > 3-y follow-up Localized hippocampal anomalies (unilateral or bilateral) Progressive (no other major associated anomaly)

Hippocampal sclerosis in dementia Discussion Hippocampal sclerosis FTLD ? Other ? Hippocampal sclerosis dementia ? Clinical evolution Localized/ extended atrophy + Dementia

Hippocampal sclerosis in dementia Discussion Blass et al. Neurology 2004; 63: White = HSclD, grey = FTD, black = AD. Symptoms at initial diagnosis

Hippocampal sclerosis in dementia Discussion White = HSclD, grey = FTD, black = AD. Blass et al. Neurology 2004; 63: Symptoms at 3-y follow-up

Hippocampal sclerosis in dementia Discussion

Hippocampal sclerosis in dementia Destruction of neuropil Gliosis FTLD-U HS HSD <<<<<<< + -

Conclusion Hippocampal sclerosis in dementia Hippocampal sclerosis in demented patients must orientate to a neurodegenerative disease, particularly FTLD Hippocampal sclerosis might be associated to vascular and some degenerative cerebral diseases Pure hippocampal sclerosis dementia is rare Neither visuoconstructive apraxia nor topographic memory troubles are seen during clincal follow-up. Atrophy and sclerosis of both hippocampi is its principal neuroradiologic anomaly

Thank you for your attention